EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors

Ondřej Fiala iD, Michaela Tkadlecová, Zuzana Váchalová, Milan Hora iD, Jan Králíček, Petr Stránský, Václav Liška, Matteo Santoni, Giuseppe Luigi Banna, Kristýna Pivovarčíková, Ondřej Topolčan, Jindřich Fínek

The Prostate · 2026-08 · 86 (11) · 1187-1194

DOI: 10.1002/pros.70197 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Prostate, online erschienen am 26.05.2026. Verfasst von Ondřej Fiala und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Phosphopyruvate Hydratase, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Univerzita Karlova v Praze, Fakultní Nemocnice Plzen, European Union's Horizon.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Outcomes of metastatic castration‐resistant prostate cancer (mCRPC) treated with androgen receptor signaling inhibitors (ARSIs) vary widely and may not be fully reflected by PSA and standard clinicopathologic factors. We evaluated the prognostic value of serum neuron‐specific enolase (NSE) at baseline and early on‐treatment dynamics.

Methods

We retrospectively analyzed ARSI‐treated mCRPC patients with available baseline NSE (n = 120). NSE was dichotomized by the upper limit of normal (ULN, 12.5 ng/mL). Radiographic progression‐free survival (rPFS) and overall survival (OS) were estimated by Kaplan–Meier methods and compared by log‐rank test. Multivariable Cox models adjusted for age, baseline PSA (per 100 ng/mL), line of therapy (2–4 vs 1), Gleason score (> 7 vs ≤ 7), metastatic timing (synchronous vs metachronous), and visceral metastases (present vs absent). NSE dynamics were evaluated using a 28‐day landmark approach among patients alive and at risk at day 28 with available baseline and week‐4 NSE (rPFS landmark n = 47; OS landmark n = 48); follow‐up was redefined from day 28 and dynamics were modeled as log2(NSE 4w /NSE 0 ) (per doubling).

Results

Median follow‐up was 44.7 months (95% CI 35.7–48.3). Baseline NSE > ULN was associated with shorter rPFS (9.4 vs 20.8 months) and OS (23.5 vs 38.2 months). In multivariable analyses, baseline NSE > ULN remained independently associated with inferior outcomes (rPFS HR 1.81, 95% CI 1.15–2.85, p = 0.011; OS HR 1.85, 95% CI 1.12–3.05, p = 0.017). In landmark models, higher NSE dynamics were independently associated with worse outcomes (rPFS HR 4.30, 95% CI 1.06–17.39, p = 0.041; OS HR 8.78, 95% CI 2.15–35.77, p = 0.002).

Conclusions

In ARSI‐treated mCRPC, baseline NSE above ULN and early 4‐week NSE dynamics provide independent prognostic information for rPFS and OS, supporting NSE as a pragmatic adjunct to clinical risk stratification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphopyruvate HydrataseProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsMaleHumansPrognosisRetrospective StudiesAgedMiddle AgedSignal TransductionBiomarkers, TumorReceptors, AndrogenNeoplasm Metastasis

Stichwörter der Autor:innen

androgen receptor signaling inhibitorsbiomarkercastration‐resistant prostate cancerneuron‐specific enolaseprognosis

Substanzen

Phosphopyruvate HydrataseAndrogen Receptor AntagonistsBiomarkers, TumorReceptors, Androgen

Autor:innen und Institutionen

  • Department of Oncology and Radiotherapeutics, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
  • ARON Research Foundation ETS, Macerata, Italy.
  • Department of Urology, Faculty of Medicine and University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Department of Surgery, University Hospital in Pilsen, Charles University, Pilsen, Czech Republic.
  • Oncology Unit, Macerata Hospital, Macerata, Italy.

ORCID-Profile: Ondřej Fiala, Milan Hora

Förderung

  • Univerzita Karlova v Praze
  • Fakultní Nemocnice Plzen
  • European Union's Horizon
  • Toyohashi University of Technology

Zitieren

APA

Fiala, O., Tkadlecová, M., Váchalová, Z., Hora, M., Králíček, J., Stránský, P., Liška, V., Santoni, M., Banna, G. L., Pivovarčíková, K., Topolčan, O., & Fínek, J. (2026). Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate, 86(11), 1187-1194. https://doi.org/10.1002/pros.70197

Vancouver

Fiala O, Tkadlecová M, Váchalová Z, Hora M, Králíček J, Stránský P, et al. Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors. The Prostate. 2026;86(11):1187-1194. doi:10.1002/pros.70197

BibTeX
@article{Fiala2026,
  author = {Fiala, Ondřej and Tkadlecová, Michaela and Váchalová, Zuzana and Hora, Milan and Králíček, Jan and Stránský, Petr and Liška, Václav and Santoni, Matteo and Banna, Giuseppe Luigi and Pivovarčíková, Kristýna and Topolčan, Ondřej and Fínek, Jindřich},
  title = {Prognostic Role of Serum Neuron‐Specific Enolase at Baseline and its Early Dynamics in Metastatic Castration‐Resistant Prostate Cancer Treated With Androgen Receptor Signaling Inhibitors},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {11},
  pages = {1187--1194},
  doi = {10.1002/pros.70197}
}
Kostenlos starten →